Shenzhen Edge Medical announced a HKEX initial public offering to raise HKD1.19 billion (about US$154 million) to fund R&D and international expansion of its surgical robotics pipeline. The company priced its offering and set a Jan. 8, 2026 listing target, with Morgan Stanley and GF Capital as joint sponsors. The IPO arrives amid a banner year for med‑tech listings: 2025 saw a surge in med‑tech IPO activity globally. Edge’s raise signals investor appetite for surgical robotics outside the largest incumbents and provides capital for clinical development, regulatory filings, and new-market launches.